Creative-Diagnostics) Proteins for SARS-CoV-2 Variants      
작성자
abbabio
작성일자
2021-07-19
조회수
317
Proteins for SARS-CoV-2 Variants
Genetic variants of SARS-CoV-2 have emerged and are circulating the world throughout the COVID-19 pandemic, such as the U.K. variant B.1.1.7, Brazil variant P.1, and South Africa variant B.1.351. The most recent Indian variant B.1.617 is particularly concerning because of its high prevalence.
Creative Diagnostics is going full steam ahead on developing a collection of recombinant antigens for these variants, including Spike proteins and Nucleocapsid proteins, covering critical mutations such as K417N/T, L452R, E484K/Q, N501Y and D614G on the Spike protein and R203G, G204R and P13L on the Nucleocapsid protein. We offer reagents that can be used to evaluate the efficacy of the antibodies and vaccinations.
The SARS-CoV-2 spike CHO-K1 cell line has been developed by the stable transfection of the SARS-CoV-2 spike protein plasmid. SARS-CoV-2 spike CHO-K1 cell line provides consistent levels of __expression__ of the SARS-CoV-2 spike protein on the cell surface.
With the demand for vaccine development, Creative Diagnostics has developed two ELISA kits for the qualitative detection of SARS-CoV-2 neutralizing antibodies in serum and plasma. Our competitive assay format measures neutralizing antibodies of the SARS-CoV-2 spike RBD and ACE2 interaction in human plasma and serum.
To understand the cell entry mechanisms of SARS-CoV-2, it is essential to study how Spike proteins interact with the ACE2 receptor. To avoid the danger of producing and manipulating live coronavirus, live SARS-CoV-2 needs to be handled under biosafety level 3 conditions.
As a supplier for global research products, Creative Diagnostics has developed a large panel of reagents for COVID-19 research. Several monoclonal antibodies developed by Creative Diagnostics have been used in COVID-19 antigen rapid test production.
Creative Diagnostics has developed several neutralizing antibodies against SARS-CoV-2. The activities of these antibodies have been extensively validated in both binding assays, and pseudovirus infection assays.
